NCT03430011 · OUTCOME

Reasons for Hospitalization From JCARH125 Administration in Phase 2

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2024-05-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: From JCARH125 infusion to up to approximately 61 months

What was measured

Number of participants with reasons for hospitalization from JCARH125 administration

Analysis population: All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol

Groups in this outcome

Phase 2 600 x 10^6 Cells

JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Phase 2 600 x 10^6 Cells	24

Reported measurements

Adverse Event

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Phase 2 600 x 10^6 Cells	3	Not reported	Not reported	Not reported	Not reported

Prophylaxis

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Phase 2 600 x 10^6 Cells	21	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
3
title
Adverse Event
categories
measurements
group Id
OG000
value
21
title
Prophylaxis

denoms

counts
group Id
OG000
value
24
units
Participants

description

Number of participants with reasons for hospitalization from JCARH125 administration

groups

description
JCARH125 IV at dose level 600 x 10\^6 consisting of CD3+CAR+T cells expansion
id
OG000
title
Phase 2 600 x 10^6 Cells

param Type

COUNT_OF_PARTICIPANTS

population Description

All participants who received at least one infusion of JCARH125 with baseline and post-baseline assessment at the respective visit in phase 2 only as prespecified in the protocol

reporting Status

POSTED

time Frame

From JCARH125 infusion to up to approximately 61 months

title

Reasons for Hospitalization From JCARH125 Administration in Phase 2

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice